Cargando…
Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern
Virus-neutralizing antibodies are one of the few treatment options for COVID-19. The evolution of SARS-CoV-2 virus has led to the emergence of virus variants with reduced sensitivity to some antibody-based therapies. The development of potent antibodies with a broad spectrum of neutralizing activity...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907979/ https://www.ncbi.nlm.nih.gov/pubmed/35281053 http://dx.doi.org/10.3389/fimmu.2022.822159 |
_version_ | 1784665775107211264 |
---|---|
author | Favorskaya, Irina A. Shcheblyakov, Dmitry V. Esmagambetov, Ilias B. Dolzhikova, Inna V. Alekseeva, Irina A. Korobkova, Anastasia I. Voronina, Daria V. Ryabova, Ekaterina I. Derkaev, Artem A. Kovyrshina, Anna V. Iliukhina, Anna A. Botikov, Andrey G. Voronina, Olga L. Egorova, Daria A. Zubkova, Olga V. Ryzhova, Natalia N. Aksenova, Ekaterina I. Kunda, Marina S. Logunov, Denis Y. Naroditsky, Boris S. Gintsburg, Alexandr L. |
author_facet | Favorskaya, Irina A. Shcheblyakov, Dmitry V. Esmagambetov, Ilias B. Dolzhikova, Inna V. Alekseeva, Irina A. Korobkova, Anastasia I. Voronina, Daria V. Ryabova, Ekaterina I. Derkaev, Artem A. Kovyrshina, Anna V. Iliukhina, Anna A. Botikov, Andrey G. Voronina, Olga L. Egorova, Daria A. Zubkova, Olga V. Ryzhova, Natalia N. Aksenova, Ekaterina I. Kunda, Marina S. Logunov, Denis Y. Naroditsky, Boris S. Gintsburg, Alexandr L. |
author_sort | Favorskaya, Irina A. |
collection | PubMed |
description | Virus-neutralizing antibodies are one of the few treatment options for COVID-19. The evolution of SARS-CoV-2 virus has led to the emergence of virus variants with reduced sensitivity to some antibody-based therapies. The development of potent antibodies with a broad spectrum of neutralizing activity is urgently needed. Here we isolated a panel of single-domain antibodies that specifically bind to the receptor-binding domain of SARS-CoV-2 S glycoprotein. Three of the selected antibodies exhibiting most robust neutralization potency were used to generate dimeric molecules. We observed that these modifications resulted in up to a 200-fold increase in neutralizing activity. The most potent heterodimeric molecule efficiently neutralized each of SARS-CoV-2 variant of concern, including Alpha, Beta, Gamma, Delta and Omicron variants. This heterodimeric molecule could be a promising drug candidate for a treatment for COVID-19 caused by virus variants of concern. |
format | Online Article Text |
id | pubmed-8907979 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89079792022-03-11 Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern Favorskaya, Irina A. Shcheblyakov, Dmitry V. Esmagambetov, Ilias B. Dolzhikova, Inna V. Alekseeva, Irina A. Korobkova, Anastasia I. Voronina, Daria V. Ryabova, Ekaterina I. Derkaev, Artem A. Kovyrshina, Anna V. Iliukhina, Anna A. Botikov, Andrey G. Voronina, Olga L. Egorova, Daria A. Zubkova, Olga V. Ryzhova, Natalia N. Aksenova, Ekaterina I. Kunda, Marina S. Logunov, Denis Y. Naroditsky, Boris S. Gintsburg, Alexandr L. Front Immunol Immunology Virus-neutralizing antibodies are one of the few treatment options for COVID-19. The evolution of SARS-CoV-2 virus has led to the emergence of virus variants with reduced sensitivity to some antibody-based therapies. The development of potent antibodies with a broad spectrum of neutralizing activity is urgently needed. Here we isolated a panel of single-domain antibodies that specifically bind to the receptor-binding domain of SARS-CoV-2 S glycoprotein. Three of the selected antibodies exhibiting most robust neutralization potency were used to generate dimeric molecules. We observed that these modifications resulted in up to a 200-fold increase in neutralizing activity. The most potent heterodimeric molecule efficiently neutralized each of SARS-CoV-2 variant of concern, including Alpha, Beta, Gamma, Delta and Omicron variants. This heterodimeric molecule could be a promising drug candidate for a treatment for COVID-19 caused by virus variants of concern. Frontiers Media S.A. 2022-02-24 /pmc/articles/PMC8907979/ /pubmed/35281053 http://dx.doi.org/10.3389/fimmu.2022.822159 Text en Copyright © 2022 Favorskaya, Shcheblyakov, Esmagambetov, Dolzhikova, Alekseeva, Korobkova, Voronina, Ryabova, Derkaev, Kovyrshina, Iliukhina, Botikov, Voronina, Egorova, Zubkova, Ryzhova, Aksenova, Kunda, Logunov, Naroditsky and Gintsburg https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Favorskaya, Irina A. Shcheblyakov, Dmitry V. Esmagambetov, Ilias B. Dolzhikova, Inna V. Alekseeva, Irina A. Korobkova, Anastasia I. Voronina, Daria V. Ryabova, Ekaterina I. Derkaev, Artem A. Kovyrshina, Anna V. Iliukhina, Anna A. Botikov, Andrey G. Voronina, Olga L. Egorova, Daria A. Zubkova, Olga V. Ryzhova, Natalia N. Aksenova, Ekaterina I. Kunda, Marina S. Logunov, Denis Y. Naroditsky, Boris S. Gintsburg, Alexandr L. Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern |
title | Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern |
title_full | Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern |
title_fullStr | Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern |
title_full_unstemmed | Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern |
title_short | Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern |
title_sort | single-domain antibodies efficiently neutralize sars-cov-2 variants of concern |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907979/ https://www.ncbi.nlm.nih.gov/pubmed/35281053 http://dx.doi.org/10.3389/fimmu.2022.822159 |
work_keys_str_mv | AT favorskayairinaa singledomainantibodiesefficientlyneutralizesarscov2variantsofconcern AT shcheblyakovdmitryv singledomainantibodiesefficientlyneutralizesarscov2variantsofconcern AT esmagambetoviliasb singledomainantibodiesefficientlyneutralizesarscov2variantsofconcern AT dolzhikovainnav singledomainantibodiesefficientlyneutralizesarscov2variantsofconcern AT alekseevairinaa singledomainantibodiesefficientlyneutralizesarscov2variantsofconcern AT korobkovaanastasiai singledomainantibodiesefficientlyneutralizesarscov2variantsofconcern AT voroninadariav singledomainantibodiesefficientlyneutralizesarscov2variantsofconcern AT ryabovaekaterinai singledomainantibodiesefficientlyneutralizesarscov2variantsofconcern AT derkaevartema singledomainantibodiesefficientlyneutralizesarscov2variantsofconcern AT kovyrshinaannav singledomainantibodiesefficientlyneutralizesarscov2variantsofconcern AT iliukhinaannaa singledomainantibodiesefficientlyneutralizesarscov2variantsofconcern AT botikovandreyg singledomainantibodiesefficientlyneutralizesarscov2variantsofconcern AT voroninaolgal singledomainantibodiesefficientlyneutralizesarscov2variantsofconcern AT egorovadariaa singledomainantibodiesefficientlyneutralizesarscov2variantsofconcern AT zubkovaolgav singledomainantibodiesefficientlyneutralizesarscov2variantsofconcern AT ryzhovanatalian singledomainantibodiesefficientlyneutralizesarscov2variantsofconcern AT aksenovaekaterinai singledomainantibodiesefficientlyneutralizesarscov2variantsofconcern AT kundamarinas singledomainantibodiesefficientlyneutralizesarscov2variantsofconcern AT logunovdenisy singledomainantibodiesefficientlyneutralizesarscov2variantsofconcern AT naroditskyboriss singledomainantibodiesefficientlyneutralizesarscov2variantsofconcern AT gintsburgalexandrl singledomainantibodiesefficientlyneutralizesarscov2variantsofconcern |